Table 3

Mortality among patients with E. coli or Klebsiella spp. bacteremia treated empirically with different antimicrobials depending on the adequacy
Adequate Inadequate p RR (95% CI)
Beta-lactam/Beta-lactam inhibitor combinations (n = 117) 11 (13.1) 13 (39.4) 0.002 0.58 (0.37-0.91)
  Amoxicillin/clavulanate (n = 67) 3 (7.5) 10 (37) 0.004 0.34 (0.12-0.92)
  Piperacillin/tazobactam (n = 50) 8 (18.2) 3 (50) 0.11 0.79 (0.54-1.14)
Quinolones (n = 62) 0) 10 (20.4) - -
Carbapenem (n = 70) 18 (25.7) - - -
Cefotaxime or ceftriaxone (n = 50) - 7 (14) - -
Aminoglycoside monotherapy* (n = 22) 3 (23.1) 2 (22.2) 0.68 1.02 (0.45-2.31)
None antimicrobial (n = 25) - 7 (28) - -
Overall (n = 387) 34 (17.2) 47 (24.9) 0.04 0.78 (0.59-1.03)

Date are no. (%) of patients. *Patients with only aminoglycoside as empirical antibiotic ESBL-E susceptible.

Peralta et al.

Peralta et al. BMC Infectious Diseases 2012 12:245   doi:10.1186/1471-2334-12-245

Open Data